Christian Faaborg Andersen MD Profile picture
Jun 20, 2023 17 tweets 9 min read Read on X
1/ Your 56-year-old patient with DM2, HTN, HLD, and a prior MI, comes to clinic reporting he stopped his statin a few weeks ago. “The muscle cramps were killing me, doc,” he tells you.

Let's take a deep dive into statin intolerance 💊🩺🫀

#tweetorial #statinintolerance Image
2/ We’ll cover these 4 Learning Objectives:

🔺List the indications for statin therapy as 1º prevention.

🔺Define statin intolerance (SI).

🔺Understand the prevalence of SI and its impact on mortality.

🔺Develop an approach to statin intolerance.
3/ I feel comfortable listing the indications for statin therapy.
4/ Statin therapy as 1º prevention:

➡️ Statins are widely prescribed to mitigate CV risk.

➡️ Common indications for statin therapy include diabetes & very elevated LDL.

➡️ ACC/AHA recommends using CV risk estimators for less clear-cut cases. Image
5/ A question ❓❓❓

What exactly is statin intolerance? Image
6/ Why does it matter?

Well, stopping statins leads to increased mortality and worse CV outcomes!

🔺 14% greater risk of all-cause mortality over 5-years!

➡️ bit.ly/AnnalsStatins

➡️ bit.ly/JAMAStatin Image
7/ This is a BIG problem, because it’s actually pretty common....

Take a guess at how common...?
8/

Well, different studies tell different stories, from 2-3% to 50%.

This 2022 @ehj_ed meta-analysis reported 9.1% of patients w/ adverse MSK effects that prevented them from using statins or limited guideline-recommended doses.

bit.ly/EHJStatinIntol… Image
9/ Sidebar: whether the MSK side-effects of statins are “real” or psychosomatic is a fascinating question, but may be a moot point if patients are stopping their statin regardless.

Nonetheless, here’s one of my favorite studies of statins vs. placebo.

bit.ly/StatinVsPlacebo Image
10/ Here’s a framework you might use when tackling statin intolerance...

For a deeper dive into the contemporary management of HLD, check out this terrific review article by @RichardAFerraro & colleagues!

bit.ly/HLDmanagement Image
11/ And do these changes to dosing patterns work?

Yes! In fact, prior work in the @AmericanHeartJ suggests that up to 72% of patients can tolerate a statin when transitioned to intermittent dosing while still achieving great LDL ⬇️

bit.ly/StatinRe-trial Image
12/ If a shared decision to re-trial a lower dose statin is unsuccessful, you would next reach for ezetimibe or a PCSK-9 inhibitor.

After that, you may consider bempedoic acid.

bit.ly/CLEAROUTCOMES Image
13/ For a deep dive into the CLEAR Outcomes Trial, check out last month’s @CardioNerdsJC from May 31st. ImageImage
14/ Today we learned:

🔺Indications for statin therapy as 1º prevention.

🔺Definition of statin intolerance (SI).

🔺The prevalence of SI and its impact on mortality.

🔺A framework to statin intolerance.
15/ I feel comfortable describing listing the indications for statin therapy and defining statin intolerance.
16/ I learned something in this Tweetorial that might change my clinical practice.
17/ To learn more, check out @CardioNerds Prevention Series Episodes 38, 39, 42 and the #DecipherTheGuidelines Q&A series!

And a BIG thanks to my friends/mentors @RichardAFerraro, @DrAlaaDiab, @dinubalanescu & @AmitGoyalMD for peer-reviewing🫀🤓 + the whole @CardioNerds fam! 🙏 Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Christian Faaborg Andersen MD

Christian Faaborg Andersen MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @CFAndersenMD

Mar 14, 2022
1/ You see a 56 y.o man with a h/o HTN, DM2 & HLD in your clinic. He’s been out of care for a while and you’re concerned about his ASCVD risk. You order a lipid panel, but wonder, “should I also add an ApoB level?”

Keep reading this @CardioNerds #tweetorial to learn more…!
2/ We’ll cover these 3 Learning Objectives

🔺Describe the role of ApoB in atherogenesis

🔺Understand the data comparing ApoB to other measures of atherogenicity

🔺Identify the practical advantages of using ApoB as a biomarker and when to order it
3/ I feel comfortable describing the role of ApoB in atherogenesis and its utility as a biomarker compared to other labs in a traditional lipid panel.
Read 18 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(